CYTOKINETICS INC (CYTK)
US23282W6057 - Common Stock
Overall CYTK gets a fundamental rating of 2 out of 10. We evaluated CYTK against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of CYTK have multiple concerns. While showing a medium growth rate, CYTK is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CYTK has reported negative net income.
In the past year CYTK has reported a negative cash flow from operations.
In the past 5 years CYTK always reported negative net income.
In the past 5 years CYTK reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of CYTK (-40.14%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.14% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-42.59%
ROA(5y)-38.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for CYTK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTK has more shares outstanding than it did 1 year ago.
CYTK has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CYTK has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -0.65, we must say that CYTK is in the distress zone and has some risk of bankruptcy.
CYTK's Altman-Z score of -0.65 is fine compared to the rest of the industry. CYTK outperforms 60.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.65 |
ROIC/WACCN/A
WACC11.45%
2.3 Liquidity
CYTK has a Current Ratio of 9.28. This indicates that CYTK is financially healthy and has no problem in meeting its short term obligations.
CYTK's Current ratio of 9.28 is fine compared to the rest of the industry. CYTK outperforms 78.41% of its industry peers.
A Quick Ratio of 9.28 indicates that CYTK has no problem at all paying its short term obligations.
CYTK has a better Quick ratio (9.28) than 78.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.54% over the past year.
The Revenue for CYTK has decreased by -58.84% in the past year. This is quite bad
CYTK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -24.89% yearly.
EPS 1Y (TTM)2.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.74%
Revenue 1Y (TTM)-58.84%
Revenue growth 3Y-48.71%
Revenue growth 5Y-24.89%
Sales Q2Q%22.49%
3.2 Future
Based on estimates for the next years, CYTK will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.90% on average per year.
Based on estimates for the next years, CYTK will show a very strong growth in Revenue. The Revenue will grow by 135.38% on average per year.
EPS Next Y0.41%
EPS Next 2Y-0.15%
EPS Next 3Y8.41%
EPS Next 5Y17.9%
Revenue Next Year-68.56%
Revenue Next 2Y67.77%
Revenue Next 3Y155.18%
Revenue Next 5Y135.39%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CYTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.15%
EPS Next 3Y8.41%
5. Dividend
5.1 Amount
No dividends for CYTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOKINETICS INC
NASDAQ:CYTK (12/20/2024, 8:04:41 PM)
After market: 48.87 0 (0%)48.87
+2.13 (+4.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners115.37%
Inst Owner Change0.32%
Ins Owners4.09%
Ins Owner Change0.31%
Market Cap5.77B
Analysts80
Price Target85.14 (74.22%)
Short Float %12.13%
Short Ratio12.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-14.2%
Min EPS beat(2)-21.59%
Max EPS beat(2)-6.82%
EPS beat(4)0
Avg EPS beat(4)-20.5%
Min EPS beat(4)-39.39%
Max EPS beat(4)-6.82%
EPS beat(8)0
Avg EPS beat(8)-25.7%
EPS beat(12)2
Avg EPS beat(12)-8.59%
EPS beat(16)2
Avg EPS beat(16)-16.5%
Revenue beat(2)0
Avg Revenue beat(2)-67.76%
Min Revenue beat(2)-73.51%
Max Revenue beat(2)-62.02%
Revenue beat(4)0
Avg Revenue beat(4)-57.33%
Min Revenue beat(4)-84.78%
Max Revenue beat(4)-9%
Revenue beat(8)1
Avg Revenue beat(8)-46.16%
Revenue beat(12)3
Avg Revenue beat(12)218.27%
Revenue beat(16)3
Avg Revenue beat(16)158.06%
PT rev (1m)1.28%
PT rev (3m)2.6%
EPS NQ rev (1m)-1.08%
EPS NQ rev (3m)-16.96%
EPS NY rev (1m)-1.15%
EPS NY rev (3m)-2.64%
Revenue NQ rev (1m)-2.83%
Revenue NQ rev (3m)115.31%
Revenue NY rev (1m)-6.76%
Revenue NY rev (3m)-18.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1791.6 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-5.38
EYN/A
EPS(NY)-5.47
Fwd EYN/A
FCF(TTM)-3.45
FCFYN/A
OCF(TTM)-3.43
OCFYN/A
SpS0.03
BVpS-0.12
TBVpS-0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -40.14% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.59%
ROA(5y)-38.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 19.97% | ||
| Cap/Sales | 83.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.28 | ||
| Quick Ratio | 9.28 | ||
| Altman-Z | -0.65 |
F-Score4
WACC11.45%
ROIC/WACCN/A
Cap/Depr(3y)783.5%
Cap/Depr(5y)631.49%
Cap/Sales(3y)33.4%
Cap/Sales(5y)25.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-0.74%
EPS Next Y0.41%
EPS Next 2Y-0.15%
EPS Next 3Y8.41%
EPS Next 5Y17.9%
Revenue 1Y (TTM)-58.84%
Revenue growth 3Y-48.71%
Revenue growth 5Y-24.89%
Sales Q2Q%22.49%
Revenue Next Year-68.56%
Revenue Next 2Y67.77%
Revenue Next 3Y155.18%
Revenue Next 5Y135.39%
EBIT growth 1Y-5.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.71%
EBIT Next 3Y0.63%
EBIT Next 5Y23.91%
FCF growth 1Y-49.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.33%
OCF growth 3YN/A
OCF growth 5YN/A